## **Erratum**

## A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis

Anne Bethune-Volters, Jean Chidiac, Okba Bensaoula, Antonio Delgado and Mario Di Palma

Anti-Cancer Drugs 2006, 17:599

The authors would like to apologize for the following errors in their Original article [1].

The first author, Slimane Khamales was omitted from the author list. The correct author list appears below.

Slimane Khamales<sup>a</sup>, Anne Bethune-Volters<sup>b</sup>, Jean Chidiac<sup>c</sup>, Okba Bensaoula<sup>b</sup>, Antonio Delgado<sup>d</sup> and Mario Di Palma<sup>a</sup>

<sup>a</sup>Oncology Department, Institut Gustave Roussy, Villejuif, <sup>b</sup>Oncology Department, Centre René Huguenin, St Cloud, <sup>c</sup>Oncology Department, Centre René Gaducheau, Saint Herbain, and <sup>d</sup>Schwarz Pharma, Boulogne, France.

## Reference

Bethune-Volters A, Chidiac J, Bensaoula J, Delgado A, Di Palma M. A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis. *Anticancer Drugs* 2006; 17:217–224.